Company news
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) news
Creative Medical Technology Holdings, Inc. news releases on 6ix. Latest, Nov 3, 2022: Creative Medical Technology Holdings Announces FDA Clearance…
Press releases — page 2
Creative Medical Technology Holdings Announces FDA Clearance of Investigational New Drug (IND) Application for AlloStem™, a Novel Cell Therapy for the Treatment of Type 1 Diabetes
November 2, 2022
Creative Medical Technology Holdings Develops AlloStem™ Clinical Cell Line
October 19, 2022
Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study
September 25, 2022
Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study
July 27, 2022
Creative Medical Technology Holdings Announces Agreement with Greenstone Biosciences, Inc. for Development of a Next Generation iPSC Pipeline for its ImmCelz® Immunotherapy Platform
June 14, 2022
Creative Medical Technology Announces $17 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 28, 2022
Creative Medical Technology Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product
April 19, 2022
Creative Medical Technology to Showcase CaverStem® at American Urological Association Annual Meeting - Largest and Most Prominent Gathering of Urologists in the World
April 11, 2022
Creative Medical Technology Signs Master Collaboration Agreement with the University of Miami to Accelerate Development of ImmCelz® Supercharged Autologous Immunotherapy Platform
March 30, 2022
Creative Medical Technology Announces Positive Top-Line Results for StemSpine® Pilot Study
March 22, 2022
Creative Medical Technology Secures Exclusive Distribution Rights for Cervos Medical's Marrow Cellution™ Devices for Use in Urology, Gynecology, and Male and Female Sexual Dysfunction
March 9, 2022
Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer
March 1, 2022
Creative Medical Technology Holdings, Inc. Prices $16 Million Public Offering and Uplisting to the Nasdaq Capital Market
December 2, 2021
Creative Medical Technology Holdings Announces Implementation of Reverse Stock Split in Preparation for Planned Uplisting to The Nasdaq Capital Market
November 8, 2021
Creative Medical Technology Holdings Reports Positive Data on ImmCelz™ Immunotherapy Product
October 11, 2021
Creative Medical Technology Holdings Files Provisional Patent on Novel Type 1 Diabetes Immunotherapy Using Exosomes from MyeloCelz™ Platform
September 30, 2021
Creative Medical Technology Holdings, Inc. Engages Established Contact Management Organization to Accelerate Adoption of CaverStem®
September 15, 2021
Creative Medical Technology Holdings Announces $3.8 Million Private Placement with Institutional Investors
August 8, 2021
Creative Medical Technology Holdings Announces MyeloCelz™ The Company's Second Regenerative Immunotherapy Product
July 19, 2021
Creative Medical Technology Holdings Recruits Renowned Stem Cell Clinical Trials Expert to Hyper-Accelerate FDA Clearance
June 21, 2021
Creative Medical Technology Holdings To Present ImmCelz® Subsidiary At World Stem Cell Conference
June 16, 2021
Creative Medical Technology Holdings Identifies Synergy Between ImmCelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes
June 8, 2021
Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease
May 23, 2021
FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz® IND for Stroke Treatment
May 13, 2021
Creative Medical Technology Holdings, Inc. to Launch Virtual Physician™ Focused on Telehealth Solutions for Regenerative Medicine
March 22, 2021
Creative Medical Technology Holdings, Inc. Announces FDA Acknowledgment of IND Application for ImmCelz® to Treat Stroke
March 15, 2021
Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine® Clinical Sites
March 9, 2021
Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine® Personalized Adult Stem Cell Therapy
March 3, 2021
Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application
March 2, 2021
Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®
February 15, 2021
Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem® Female Infertility/Ovarian Failure Treatment
February 9, 2021
Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board
February 7, 2021
Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity
January 31, 2021
Creative Medical Technology Holdings Recruits Founder of Inc 500 Clinical Trials Company Dr. Boris Reznik to Accelerate Development of ImmCelz® Through FDA
January 20, 2021
Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes
January 18, 2021
Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy
January 11, 2021
ImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients
January 5, 2021
Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz® Regenerative Immunotherapy
December 30, 2020
Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model
December 28, 2020
Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity
December 21, 2020
Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke
December 15, 2020
Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy
December 9, 2020
Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model
September 28, 2020
Creative Medical Technology Holdings, Inc. September 2020 Shareholder Update
September 23, 2020
Creative Medical Technology Holdings Identifies Novel Mechanism of Action of AmnioStem™ Adult Stem Cell Product in Stroke
August 19, 2020
Creative Medical Technology Holdings Completes AmnioStem™ Preclinical Studies Needed for FDA Investigational New Drug Application Filing
July 8, 2020
Creative Medical Technology Holdings is Granted Patent on Mesenchymal Stem Cells for Female Infertility Pending Quayle Action
April 19, 2020
Creative Medical Technology Holdings Announces IMMCELZ™ Adoptive Immunotherapy Product
March 10, 2020